3 results
To assess the safety and tolerability profile of durvalumab monotherapy, durvalumab + novel oncology therapy, durvalumab + chemotherapy, anddurvalumab + novel oncology therapy + chemotherapy combinations
The main goal of this study is the pharmacokinetic evaluation of a 30 mg and a 60 mg pulmonary administered levodopa with 2% l-leucine dry powder dose. The results gained with this study which will be used for further optimalisation and dose…
Pilot study:Primary objective: feasibilitySecondary objectives: response rate, time to progression, overall survival and quality of life.Phase II study:Primary objective: efficacy.Secondary objectives: toxicity, especially grade 3 and 4 toxicities,…